How does Evenity work?

Evenity (romosozumab-aqqg) is a humanized monoclonal antibody that works by inhibiting the activity of sclerostin, which is a small protein found in osteocytes. It increases bone formation and reduces bone loss.

Evenity was approved in April 2019 for postmenopausal women at high risk of fracture and is given by injection by a healthcare provider once a month for a treatment period of 12 months. After the 12-month course, therapy should continue with an anti-resorptive agent.

The main side effects associated with Evenity are joint pain (arthralgia) and headache. Evenity can also increase a woman's risk of having a heart attack and stroke, and for this reason, it carries a boxed warning, and should not be given to women with other cardiovascular risk factors.